Ignite Creation Date:
2024-05-05 @ 6:47 PM
Last Modification Date:
2024-10-26 @ 9:36 AM
Study NCT ID:
NCT00540072
Status:
COMPLETED
Last Update Posted:
2019-11-14
First Post:
2007-10-04
Brief Title:
Study of Cidecin Daptomycin to Rocephin Ceftriaxone in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S Pneumoniae
Sponsor:
Cubist Pharmaceuticals LLC a subsidiary of Merck Co Inc Rahway New Jersey USA
Organization:
Cubist Pharmaceuticals LLC a subsidiary of Merck Co Inc Rahway New Jersey USA
Organization Data
Organization:
Cubist Pharmaceuticals LLC a subsidiary of Merck Co Inc Rahway New Jersey USA
Class:
INDUSTRY
Study ID:
DAP-CAP-00-08
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Cubist Pharmaceuticals LLC a subsidiary of Merck Co Inc Rahway New Jersey USA
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None